Back to results
US 2026/0090986 A1Published application
Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
AssigneeChiesi Farmaceutici S.p.A.
InventorsFrancesca BUTTINI, Giada VARACCA, Romina OSELLO
Life of this patent
Estimating the term…
Abstract
The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition filled in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a drug product or a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.
Claims13
1:
- A drug product, comprising a single-dose dry powder inhalation device, comprising an inhaler body (2) defining a recess (3) for a capsule (4), wherein the capsule (4) holds herein a pharmaceutical composition to be inhaled, a nosepiece or mouthpiece (5) communicating with the recess (3), at least one rupturing element (7) coupled to the inhaler body (2) and configured for rupturing the capsule (4) to allow an outside airflow to be mixed with the pharmaceutical composition of the capsule (4) and inhaled through the nosepiece or the mouthpiece (5), and
- a pharmaceutical composition filled in a capsule, the pharmaceutical composition comprising micronized particles having a size of from 0.1 to 15 microns of the compound of formula (I)
- and a carrier consisting of a mixture of coarse and fine particles of pharmaceutically inert acceptable excipient,
- wherein the inspiratory flow rate of said inhalation device is from 30 l/min to 65 l/min and
- wherein the carrier consists of a mixture of coarse and fine particles of a physiologically acceptable inert excipient in a ratio comprised of from 70:30 to 95:5 by weight,
- the coarse particles have an equivalent volume diameter of from 200 to 500 micron,
- the fine particles have a dv(0.1) of from 1 to 5 μm, a dv(0.5) of from 18 to 30 μm, and a dv(0.9) of from 65 to 95 μm, as measured by means of laser diffraction or a sieve analyzer.
4 more elements
2:
- The drug product according to claim 1, wherein the carrier is selected from the group consisting of a polyol, a crystalline sugar, an inorganic salt, an organic salt, an organic compound, a polysaccharide, and an oligosaccharide.
3:
- The drug product according to claim 1, wherein the coarse particles have an equivalent volume diameter of from 300 to 480 micrometers.
4:
- The drug product according to claim 3, wherein the coarse particles have an equivalent volume diameter of from 350 to 450 micrometers.
5:
- The drug product according to claim 1, wherein the inspiratory flow rate is from 40 l/min to 65 l/min.
6:
- The drug product according to claim 1, wherein the unitary nominal dose of the compound of formula (I) is from 400 to 800 μg.
7:
- The drug product according to claim 6, wherein the unitary nominal dose of the compound of formula (I) is 400 μg.
8:
- The drug product according to claim 6, wherein the unitary nominal dose of the compound of formula (I) is 800 μg.
9:
- A method for the treatment of a respiratory disease, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising micronized particles having a size of from 0.1 to 15 microns of the compound of formula (I)
- and a carrier for use for the treatment of a respiratory disease,
- wherein said composition is administered using a single-dose dry powder inhalation device,
- wherein the inspiratory flow rate of said inhalation device is from 30 l/min to 65 l/min, and
- wherein the carrier consists of a mixture of coarse and fine particles of a physiologically acceptable inert excipient in a ratio comprised between 70:30 and 95:5 by weight,
- the coarse particles have an equivalent volume diameter of from 200 to 500 microns, as measured by means of laser diffraction or a sieve analyzer,
- the fine particles have a dv(0.1) of from 1 to 5 μm, a dv(0.5) of from 18 and 30 μm, and a dv(0.9) of from 65 and 95 μm, as measured by means of laser diffraction or a sieve analyzer.
4 more elements
10:
- The method according to claim 9, wherein the respiratory disease is selected from asthma and chronic obstructive pulmonary disease (COPD).
11:
- The method according to claim 9, wherein the total daily dose of the compound of formula (I) is from 800 to 4800 μg.
12:
- The method according to claim 11, wherein the total daily dose of the compound of formula (I) is from 1600 to 3200 μg.
13:
- A process for the preparation of the drug product according to claim 1, said process comprising:
- i) sieving the compound of formula (I) through a suitable mesh,
- ii) adding the carrier particles to the compound of formula (I),
- iii) sieving the final blend and mixing to obtain the pharmaceutical composition,
- iv) filling the obtained pharmaceutical composition in a capsule, and
- v) loading the capsule into a medicament chamber of a single dry powder inhalation device.
3 more elements